# Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer

> **NCT00453167** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 35 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00453167
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2010-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453167, "Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00453167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*